Expect to See More Admitted Patients Taking Empagliflozin or Liraglutide at Home
August 2016
New evidence will raise questions about cardiovascular benefits of type 2 diabetes meds.
Diabetes meds are commonly picked based on their A1C lowering, side effects, cost, etc. But now CV impact will also be important.
In fact, the SGLT2 inhibitor empagliflozin (Jardiance) is poised to become the first diabetes med approved for reducing CV death in patients with type 2 diabetes and CV disease. It prevents CV death in one in 45 patients over 3 years...and overall mortality in one in 39 patients.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote